Klasik Tedaviye Dirençli Romatoid Artrit ve Ankilozan Spondilit Hastalarında Tümör Nekroz Faktör Alfa Blokeri Kullanımının Böbrek Fonksiyonları Üzerine Etkisi

Year 2025, Volume: 51 Issue: 1, 45 - 49, 27.05.2025

Oğuzhan Öztürk , Mehmet Sezen , Tuncay Dağel

https://doi.org/10.32708/uutfd.1602162

Abstract

Romatoid Artrit (RA) ve Ankilozan Spondilit (AS) kronik, inflamatuar, sistemik hastalıklardır. Bu hastalıklar kontrol altına alınmadığında hastalarda morbidite ve mortalitede artışa neden olmaktadır. Genellikle eklem tutulumu görülmesine rağmen inflamatuar süreçten vücudun diğer organları da olumsuz etkilenebilmektedir. RA ve AS’nin patogenezinde proinflamatuar sitokin olan tümör nekrozis faktör-α’nın (TNF-α) rolü olduğu anlaşılmiştır. Bu nedenle tedavi amaçlı anti- TNF-α ajanlar geliştirilmiştir. Özellikle de hastalığı modifiye edici antiromatizmal ilaçlara (DMARD) dirençli hastalarda etkin oldukları gösterilmiştir. . Biz bu çalışmamızda DMARD’a dirençli RA ve AS hastalarında etanersept tedavisinin böbrek fonksiyonları ve hasar markırları üzerine olan etkisini araştırmayı amaçladık. Çalışmaya Kasım 2005-Ağustos 2006 tarihleri arasında Uludağ Üniversitesi İç Hastalıkları Ana Bilim Dalı Romatoloji Bilim Dalı polikliniğine başvuran 11 RA ve 8 AS hastası alındı. Hastalara haftada iki kez subkutan 25 mg dozunda etanersept tedavisi başlandı. Tedavi öncesi, tedaviden sonra 4. hafta ve 16. haftalarda, kreatinin klirensi, serum sistatin-c, serum β-2 mikroglobulin, 24 saatlik idrarda N asetil β-D glukozaminidaz (NAG) ve mikroalbuminüri düzeyleri araştırıldı. Tedavi sonunda hem serum ve hem de idrarda bakılan parametrelerde tedavi öncesine göre istatiksel açıdan anlamlı olmayan değişiklikler gözlendi. Sonuç olarak; çalışmamızda, DMARD tedavisi alan RA ve AS hastalarında etanersept tedavisinin böbreğin glomerüler ve proksimal tübül fonksiyonları üzerine olumlu ya da olumsuz bir etkisinin olmadığını saptadık.

Keywords

Romatoid Artrit, Ankilozan Spondilit, Etanersept, N asetil β-D glukozaminidaz, sistatin-c

Rheumatoid Arthritis Resistant to Conventional Treatment The Effect of Tumor Necrosis Factor Alpha Blocker Use on Renal Functions in Patients with Ankylosing Spondylitis

Abstract

Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) are chronic, inflammatory, systemic diseases. When these diseases are not controlled, they cause an increase in morbidity and mortality in patients. Although joint involvement is usually seen, other organs of the body can also be negatively affected by the inflammatory process. Tumor necrosis factor-α (TNF-α), a proinflammatory cytokine, has been implicated in the pathogenesis of RA and AS. Therefore, anti-TNF-α agents have been developed for therapeutic purposes. They have been shown to be especially effective in patients resistant to disease-modifying antirheumatic drugs (DMARDs). Among these, etanercept, infliximab and adalimumab have been approved by the US National Food and Drug Administration (FDA). There are not enough studies in the literature investigating the effects of these drugs on renal function. In this study, we aimed to investigate the effect of etanercept treatment on renal function in DMARD-resistant RA and AS patients. Between November 2005 and August 2006, 11 RA and 8 AS patients admitted to the outpatient clinic of the Department of Internal Medicine, Division of Rheumatology, Uludag University were included in the study. Patients were started on etanercept at a dose of 25 mg subcutaneously twice a week. Creatinine clearance, serum cystatin-c, serum β-2 microglobulin, N-acetyl β-D glucosaminidase (NAG) in 24-hour urine and microalbuminuria levels were investigated. At the end of treatment, statistically insignificant changes were observed in both serum and urinary parameters compared to pretreatment. In conclusion; in our study, we found that etanercept treatment had no positive or negative effect on glomerular and proximal tubule functions of the kidney in RA and AS patients receiving DMARD treatment.

Keywords

Rheumatoid Arthritis, Ankylosing Spondylitis, Etanercept, N acetyl β-D glucoseaminidase, Cystatin-c

References

• 1. Harris ED. Clinical Features of Rheumatoid Arthritis. In:Kelley WN, Harris ED, Ruddy S, Sledge CB (eds). Textbook of Rheumatology. Philadelphia: W.B. Saunders Company, 874-911, 1993.
• 2. BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology A. Keat, N. Barkham, A. Bhalla, K. Gaffney, H. Marzo-Ortega, S. Paul, F. Rogers, M. Somerville, R. Sturrock and P. Wordsworth on behalf of the BSR Standarts, Guidelines and Audit Working Group. Rheumatology 2005; 44:939- 947.
• 3. Wolheim FA: Ankylosing spondylitis: Texbook of Rheumatology. Kelley WN, Haris ED, Ruddy S, Sledge CB (ed), Wb Saunders Company, Philladelphia, 943-960, 1993.
• 4. American Collage of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheumatism 2002; Vol. 46, No.2, pp 328-346.
• 5. G. R. Smith, K. E. Tymms and M.Falk. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Internal Medicine Journal 2004; 34: 570-572.
• 6. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 1991; 70: 246-56.
• 7. Komatsuda A, Morita K, Ohtani H, Yamaguchi A, Miura AB. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate. Am J Kidney Dis 1998; 32: E7.
• 8. P. Verschueren, F. Lensen, E. Lerut, K. Claes, R. De Vos,B. Van Damme, R. Westhovens. Benefit of anti TNF-α treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003; 62: 368-369.
• 9. Leslie Garrison, Neil D McDonnell. Etanercept: therapeutic use in patiens with rheumatoid arthritis. Ann Rheum Dis 1999; 58(Suppl I) 165-169.
• 10. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor-α but not tumor necrosis factor-β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 3I:1041-5.
• 11. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
• 12. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 989;ii:244-7.
• 13. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999;130:478-86.
• 14. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptorFc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9
• 15. Geborek p, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
• 16. Edward C. Keystone, Michael H. Schiff, Joel M. Kremer, Shelly Kafka, Michael Lovy, Todd De Vries, Daniel J.Burge. Once-Weekly Administration of 50 mg Etanercept in Patients With Active Rheumatoid Arthritis. Arthritis Rheumatism Vol. 50, No. 2, February 2004, pp 353-363.
• 17.Michael B. Stokes, Kirk Foster, Glen S. Markowitz, Farhang Ebrahimi, William Mines, Darren Kaufman, Brooke Moore,Daniel Wolde, Vivette D. D’Agati. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406.
• 18.Kemp E, Nielsen H, Petersen LJ et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol 2001; 55: 87-88.
• 19.Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clinical Nephrology2004; 62: 234-238.
• 20.Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment ofrheumatoid arthritis. Semin Arthritis Rheum. 2000 Dec;30(3):196-208. Review.
• 21.Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary toinflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003 Jul;48(7): 2019-24.
• 22.Kumin CM, Chesney RW, Craig WA, England AC, De AngelisC.Enzymuria as a marker of renal injury and disease: studies of N-acetyl-h-D-glucosaminidase oin the general population and in patients with renal disease. Pediatrics 1978;62:751– 60.
• 23.P. Wiland, J. Swierkot, J. Szechinski. N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator ofkidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Br J Rheumatol. 1997 Jan; 36(1): 59-63.
• 24.Lipsky PE, van der Heijde D, St. Clair EW, Furst DE,Breedveld FC, Kalden JR, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med 2000; 343:1594-602.
• 25.Marte S. Heiberg, Bjorn-Yngvar Nordvag, Knut Mikkelsen,Erik Rodevand, Cecilie Kaufmann, Petter Mowinckel and ToreK.Kvien. The Comparative Effectiveness of Tumor Necrosis Factor-Blocking Agents in Patients With Rheumatoid Arthritis and Patients With Ankylosing Spondylitis. Arthritis Rheumatism, vol. 52, No. 8, August 2005, pp 2506-2512.
• 26.Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 2008 Apr;58(4):947-52.
• 27.Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J,Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230-6.
• 28.J. Brandt, J. Listing, H. Haibel, H. Sörensen, A. Schwebig, M. Rudwaleit, J. Sieper, J. Braun. Long-term efficacy and safety ofetanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005; 44: 342-348.
• 29.Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003; 61:137-141
• 30.Sozeri B, Gulez N, Ergin M, Serdaroglu E. The experience ofcanakinumab in renal amyloidosis secondary to Familial Mediterranean fever. Mol Cell Pediatr. 2016 Dec;3(1):33.
• 31.Sevillano ÁM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, Praga M. Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterraneanfever and amyloidosis. Nefrologia. 2016;36(1):63-6. English, Spanish.
• 32.Wiland P, Wiela-Hojenska A, Glowska A, Chlebicki A,Hurkacz M, Orzechowska-Juzwenko K, Szechinski J. Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab. Clinical and Experimental Rheumatology. 2004 Tem-Auğ;22(4): 469-72.